Opinion|Videos|May 14, 2024
Applying NCCN Guidelines in the Treatment of mBC
Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.
Advertisement
Episodes in this series
Advertisement
Related to this article
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.
Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
3
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
4
C difficile Survivor and PLF Board Member Describes the Counseling Gap Pharmacists Can Close
5